Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/73787
Title: | Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study | Authors: | Carmona-Bayonas, Alberto Jiménez-Fonseca, Paula Echaburu, Juan Virizuela Antonio, Maite Font, Carme Biosca, Mercè Ramchandani, Avinash Martínez, Jerónimo Cubero, Jorge Hernando Espinosa, Javier De Castro, Eva Martínez Ghanem, Ismael Beato, Carmen Blasco, Ana Garrido, Marcelo Bonilla, Yaiza Mondéjar, Rebeca Lanza, María Ángeles Arcusa Manrique, Isabel Aragón Manzano, Aránzazu Sevillano, Elena Castañón, Eduardo Cardona, Mercé Martín, Elena Gallardo Armillas, Quionia Pérez Lasheras, Fernando Sánchez De La Peña, Francisco Ayala |
UNESCO Clasification: | 320101 Oncología | Issue Date: | 2015 | Journal: | Journal of Clinical Oncology | Abstract: | Purpose: To validate a prognostic score predicting major complications in patients with solid tumors and seemingly stable episodes of febrile neutropenia (FN). The definition of clinical stability implies the absence of organ dysfunction, abnormalities in vital signs, and major infections. Patients and Methods: We developed the Clinical Index of Stable Febrile Neutropenia (CISNE), with six explanatory variables associated with serious complications: Eastern Cooperative Oncology Group performance status ≥ 2 (2 points), chronic obstructive pulmonary disease (1 point), chronic cardiovascular disease (1 point), mucositis of grade ≥ 2 (National Cancer Institute Common Toxicity Criteria; 1 point), monocytes < 200 per μL (1 point), and stress-induced hyperglycemia (2 points). We ntegrated these factors into a score ranging from 0 to 8, which classifies patients into three prognostic classes: low (0 points), intermediate (1 to 2 points), and high risk (≥ 3 points). We present a multicenter validation of CISNE. Results: We prospectively recruited 1,133 patients with seemingly stable FN from 25 hospitals. Complication rates in the training and validation subsets, respectively, were 1.1% and 1.1% in low-, 6.1% and 6.2% in intermediate-, and 32.5% and 36% in high-risk patients; mortality rates within each class were 0% in low-, 1.6% and 0% in intermediate-, and 4.3% and 3.1% in high-risk patients. Areas under the receiver operating characteristic curves in the validation subset were 0.652 (95% CI, 0.598 to 0.703) for Talcott, 0.721 (95% CI, 0.669 to 0.768) for Multinational Association for Supportive Care in Cancer (MASCC), and 0.868 (95% CI, 0.827 to 0.903) for CISNE (P = .002 for comparison between CISNE and MASCC). Conclusion: CISNE is a valid model for accurately classifying patients with cancer with seemingly stable FN episodes. | URI: | http://hdl.handle.net/10553/73787 | ISSN: | 0732-183X | DOI: | 10.1200/JCO.2014.57.2347 | Source: | Journal of Clinical Oncology [ISSN 0732-183X], v. 33 (5), p. 465-471, (Febrero 2015) |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
119
checked on Mar 30, 2025
WEB OF SCIENCETM
Citations
102
checked on Mar 30, 2025
Page view(s)
79
checked on Aug 10, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.